Integra Therapeutics
Agent22Agent Readiness: 22/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Biotech company developing next-generation gene writing tools for advanced therapies.
About
Integra Therapeutics is a biotechnology company focused on developing innovative gene writing tools to enhance the safety, precision, and efficacy of advanced therapies. Their lead technology, FiCAT, combines CRISPR precision with the efficiency of viral integrases and transposases to enable programmable delivery of large DNA sequences, aiming to overcome key limitations in gene therapy for genetic, oncological, and autoimmune diseases.
Key facts
At-a-glance profile data
- Website
- integra-tx.com
- Headquarters
- Barcelona, Spain
- Founded
- 2020
- Employees
- 24
- Total funding
- $135M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 8 Sept 2025 | Pre-Series A | $11M | EIC Fund, CDTI Innvierte |
| 8 Sept 2025 | Series A | $116M | MPM Capital, Deep Track Capital |
| 1 Sept 2023 | Undisclosed round | $3M | - |
| 1 Jan 2023 | Undisclosed round | $2M | - |
| 17 May 2022 | Undisclosed round | $5M | AdBio Partners, Invivo Capital |
Tech stack
Detected on integra-tx.com, last scanned 23 Jul 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Google Workspace
Frequently asked
How much funding has Integra Therapeutics raised?
Integra Therapeutics has raised a total of $135M in funding. The most recent round on record is Series A.
How many employees does Integra Therapeutics have?
Integra Therapeutics has approximately 24 people on record.
What is Integra Therapeutics's current status?
Integra Therapeutics's current operating status is: Inactive.